Japanese pharmaceutical firm Shionogi & Co. said Friday it has applied for approval of its oral COVID-19 drug, after mid-phase clinical trials showed efficacy in reducing the coronavirus in the body.It is the first such pill developed by a Japanese drugmaker and will be administered to mild-to-moderate coronavirus patients, regardless of whether they are at risk of hospitalization, to prevent the virus from multiplying in the body.The Osaka-based firm said it had filed with the Health, Labor and Welfare Ministry for conditional early approval of the drug known as S-217622, following the res…READ FULL ARTICLE
